The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, talks on the implementation of circulating tumor cells (CTCs) in prostate cancer. Current data suggests CTCs are a promising non-invasive prognostic and predictive biomarker for prostate cancer. As lutetium PSMA-based therapies join the treatment arsenal for castration-resistant prostate cancer (CRPC), there will be an increasing need to perform non-invasive methods to assess treatment response and identify patients who will benefit most from treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
